This specific tumor type is well-suited for targeting by CSF-1/CSF-1R pathway blockade; and treatment with anti-CSF-1R antibodies has shown significant reduction of CSF-1R+ TAMs within tumor tissues (97). The gene discussed is CSF1R; the disease is neoplasm.